North America Uterine Cancer Diagnostics & Treatment Market Size (2024 - 2029)

The North America Uterine Cancer Diagnostics & Treatment Market is projected to experience growth over the forecast period, driven by increasing awareness of uterine cancer, rising case numbers, and advancements in drug development and technology. The market's expansion is further supported by the approval of new treatments, which are expected to enhance diagnostic and therapeutic options. Despite these positive trends, challenges such as the high cost of research and development, expensive treatment options, and a low success rate in clinical trials may impede market growth.

Market Size of North America Uterine Cancer Diagnostics & Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
North America Uterine Cancer Diagnostics & Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 9.57 Billion
Market Size (2029) USD 11.77 Billion
CAGR (2024 - 2029) 4.22 %
Market Concentration Low

Major Players

North America Uterine Cancer Diagnostics & Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

North America Uterine Cancer Diagnostics & Treatment Market Analysis

The North America Uterine Cancer Diagnostics & Treatment Market size is estimated at USD 9.57 billion in 2024, and is expected to reach USD 11.77 billion by 2029, growing at a CAGR of 4.22% during the forecast period (2024-2029).

The COVID-19 pandemic impacted the healthcare systems globally and significantly impacted the North American uterine cancer diagnostics and treatment market. For instance, according to the article published in November 2021 by Cancer Connect, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46.0% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers in North America. Moreover, in the COVID-19 era, nearly 88.0% of the cancer care centers faced challenges in delivering usual cancer care for many reasons, including preventive measures, lack of personal protective equipment, and staff shortage, as per the NCBI research article published in 2021. However, with the resumption of all non-essential surgeries and medical requirements, the market has started to gain traction. It is expected to continue the upward trend over the forecast period.

The major drivers for the market are the rising awareness about uterine cancer and the available therapies, increasing cases of uterine cancer, innovation in drug development, and subsequent technological advancements. For instance, according to the American Cancer Society estimates for cancer of the uterus in the United States for 2023, around 66,200 new cases of cancer of the body of the uterus (uterine body or corpus) will be diagnosed, and around 13,030 women will die from cancers of the uterine body in 2023. The same source also stated that endometrial cancer affects mainly post-menopausal women. The average age of women diagnosed with endometrial cancer is 60. It's uncommon in women under the age of 45. Thus, increasing cases of uterine cancer are expected to propel the demand for uterine cancer diagnostics and treatment, thereby propelling market growth.

The increasing product approval for treating uterine cancer diagnostics is also expected to propel the market growth over the forecast period. For instance, in April 2021, the U.S. FDA granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Similarly, Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Thus, increasing product approvals is anticipated to positively impact the market growth over the forecast period.

However, the low success rate in clinical trials for cancer drugs, the high cost of research and development, and the high cost associated with the treatment will likely hinder the market growth over the forecast period.

North America Uterine Cancer Diagnostics & Treatment Industry Segmentation

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. Risk factors associated with this cancer are being overweight and starting periods at an early age. 

North America's uterine cancer diagnostics and treatment market is segmented by cancer type (endometrial cancer, uterine sarcoma), procedure (surgery, immunotherapy, radiation therapy, chemotherapy, and other treatments), diagnostics (biopsy, ultrasound, hysteroscopy, dilation and curettage, and other diagnostics), and geography (North America, Europe, Asia-Pacific, the Middle East, Africa, and South America). 

The report offers the value (in USD) for the above segments.

By Cancer Type
Endometrial Cancer
Uterine Sarcoma
By Procedure
Treatment
Surgery
Immunotherapy
Radiation Therapy
Chemotherapy
Other Treatments
Diagnostics
Biopsy
Ultrasound
Hysteroscopy
Dilation and Curettage
Other Diagnostics
Geography
North America
United States
Canada
Mexico
Need A Different Region Or Segment?
Customize Now

North America Uterine Cancer Diagnostics & Treatment Market Size Summary

The North American uterine cancer diagnostics and treatment market is poised for significant growth over the forecast period, driven by increasing awareness of uterine cancer, advancements in drug development, and technological innovations. The market, which experienced disruptions due to the COVID-19 pandemic, is recovering as healthcare systems resume normal operations. The rising incidence of uterine cancer, particularly among post-menopausal women, is expected to boost demand for diagnostics and treatment solutions. The market is further supported by the approval of new therapies and drugs, such as Jemperli and KEYTRUDA, which target specific genetic features of endometrial cancer. These developments are anticipated to enhance treatment options and improve patient outcomes, thereby propelling market expansion.

In the United States, the uterine cancer diagnostics and treatment market is experiencing growth due to high healthcare expenditure, a concentration of market players, and strategic partnerships among major companies. The substantial investment in research and development is expected to accelerate the approval of new uterine cancer drugs, contributing to market growth. Key product launches and approvals, such as MYFEMBREE for managing endometriosis and uterine fibroids, are also driving market dynamics. The presence of global players like Merck & Co. Ltd, Pfizer Inc., and AbbVie Inc. underscores the competitive landscape, with ongoing research and development efforts likely to attract more entrants into the market.

Explore More

North America Uterine Cancer Diagnostics & Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Awareness about Uterine Diseases and the Available Therapies

      2. 1.2.2 Increasing Health Care Expenditure

      3. 1.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 Low Success Rate in Clinical Trials for Cancer Drugs and High Cost of Research and Development

      2. 1.3.2 High Cost Associated with the Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value – USD) 

    1. 2.1 By Cancer Type

      1. 2.1.1 Endometrial Cancer

      2. 2.1.2 Uterine Sarcoma

    2. 2.2 By Procedure

      1. 2.2.1 Treatment

        1. 2.2.1.1 Surgery

        2. 2.2.1.2 Immunotherapy

        3. 2.2.1.3 Radiation Therapy

        4. 2.2.1.4 Chemotherapy

        5. 2.2.1.5 Other Treatments

      2. 2.2.2 Diagnostics

        1. 2.2.2.1 Biopsy

        2. 2.2.2.2 Ultrasound

        3. 2.2.2.3 Hysteroscopy

        4. 2.2.2.4 Dilation and Curettage

        5. 2.2.2.5 Other Diagnostics

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

North America Uterine Cancer Diagnostics & Treatment Market Size FAQs

The North America Uterine Cancer Diagnostics & Treatment Market size is expected to reach USD 9.57 billion in 2024 and grow at a CAGR of 4.22% to reach USD 11.77 billion by 2029.

In 2024, the North America Uterine Cancer Diagnostics & Treatment Market size is expected to reach USD 9.57 billion.

North America Uterine Cancer Diagnostics & Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)